

INDEX

A

- abciximab 117,118,120,151,158
- ablation and pacing therapy 269
- ACE inhibitors
 - and aspirin 78, 172-173, 209, 225
 - for heart failure 204-212, 216, 244
 - for hypertension 78
 - for stable angina 104
 - to prevent heart failure after MI 172-174
 - versus angiotensin receptor blockers for HF 221-222
- active chest compression-decompression 129
- ACTIVE for LIFE 44
- acute coronary syndromes
 - assessment in the emergency department 133-137
 - cardiac rehabilitation 162-167
 - guidelines and audit 140, 161-162
 - heart failure post ACS 171-174
 - information and advice to patients 132-133
 - non-invasive investigations 159-160
 - percutaneous coronary intervention 150-158, 170-171
 - post ACS therapies 141-150
 - prehospital care 127-131, 140
 - risk stratification at discharge 168
 - secondary prevention 174-196
 - thrombolysis 138-139
- advanced heart failure, see severe heart failure
- advanced life support for cardiac arrest 131
- advice & relaxation tape after MI 150
- AFASAK 261
- AFCAPS/TexCAPS 64
- AF-CHF 219
- AFFIRM 253
- African American women, hypertension therapy 59
- Afro-caribbeans, atrial fibrillation 267
- aggressive lipid-lowering 105, 187
- AIRE 206
- ALLHAT 65, 76
- alcohol consumption 10, 22, 85, 242
- algorithm
 - for heart failure 227
 - for hypertension 89
- amiodarone 190, 218, 233, 256, 257
- amlodipine 80, 226, 246
- angiography 94
- angioplasty 110-115, 149, 170, 171
- angiotension converting enzyme inhibitors, see ACE inhibitors
- angiotensin receptor blockers for heart failure
 - 80, 174, 221-223
- antiarrhythmics
 - for cardioversion 256-258
 - for heart failure 218-219, 224
 - for secondary prevention after ACS 190
- anticoagulants 145, 191, 224, 255, 261-268
- antioxidant vitamins
 - in primary prevention 23
 - in secondary prevention 195
- antiplatelet therapy
 - 73, 78, 100-102, 141-145, 172-173, 180-182
 - see also, aspirin, clopidogrel 209, 225, 261, 266
- antithrombotic therapy 102, 191, 261-268, 270
- anxiety
 - as a risk factor 27
 - in heart failure 242
- anxiolytics for smoking cessation 35
- APRICOT-2 191
- Asian patients and statin therapy 59
- ASPECT-2 191
- aspirin
 - and ACE inhibitors 78, 172-173, 209, 225
 - for acute coronary syndromes 141-145
 - for atrial fibrillation 261, 266
 - for heart failure 225
 - for hypertension 73
 - for secondary prevention after ACS 180-182
 - for stable angina/CHD 100-102
 - long term 101
 - low dose in primary prevention 102

INDEX

- losartan, see also angiotensin receptor blockers 77, 222
- lycopene as risk factor 27
- M**
- magnesium sulphate for pre-hospital cardiac arrest 140
- management training seminars for health promotion 51
- manganese for primary prevention 23
- mass media interventions 30, 133
- MDC study 214
- mediterranean dietary pattern 195
- MERIT 216, 245
- metoprolol, see also beta blockers 214, 216, 245
- microwaves for atrial fibrillation 268
- MIRACLE study 183, 233
- mitral valve repair 236
- moclobemide for smoking cessation 35
- mononitrate, oral post ACS 149
- MRC/BHF Heart Protection study 68
- myocardial infarction, see acute coronary syndromes
- Myocardial Infarction Audit Project (MINAP) 162
- myocardial perfusion scintigraphy 99, 160
- myopathy, and statin therapy 66
- N**
- nebivolol for heart failure 216
- NETWORK investigators 208
- NICE trials 152
- NICE guidelines, see guidelines
- nicorandil for stable angina 104
- Nicotine Replacement Therapy (NRT) 34
- nifedipine for secondary prevention 193
see also calcium channel blockers
- nitroglycerin for stable angina 103
- nurse-led management 178, 237, 238, 264
- nurses
and nutrition of heart failure patients 239
and interventions for smoking cessation 34, 164
and risk assessment 54
- O**
- obesity and overweight 6, 17-19, 42, 86
- oestrogen replacement, see hormone replacement therapy
- omega-3 fatty acids 41
- OPTIME-CHF 224
- oral anticoagulants, see anticoagulants
- orlistat 70
- OSCUR 239
- out-of-hospital, see pre-hospital
- overweight, see obesity and overweight
- P**
- pacemaker 269
- PAD study 131
- palliative management of heart failure 247
- PATAF 261
- patient decision aids for health treatment/screening 61
- patient information 61, 132
- percutaneous coronary intervention (PCI) 112-119, 154-158
- percutaneous transluminal coronary angioplasty (PTCA),
see PCI
- percutaneous transluminal coronary rotational
atherectomy (PTCRA), see PCI
- percutaneous transmyocardial laser revascularisation 125
- perfusion scintigraphy 95

INDEX

perindopril			
for heart failure	208		
for hypertension	78		
see also ACE inhibitors			
pharmacists	242-243		
phosphodiesterase inhibitors for heart failure	220-221		
physical activity, see exercise			
PIAF	254		
Pol-GIK	149		
POST study	91, 177		
potassium supplements for hypertension	84		
practice guidelines, see guidelines			
pravastatin, see also statins	65, 67		
PRECARD(R)	55		
pre-hospital			
cardiac arrest	130		
ECG	136		
management of thrombolysis	138-140		
pre-operative education before revascularisation	116		
prevalence/incidence			
of atrial fibrillation	249-250		
of death from CHD	6		
of heart failure	198-199		
procainamide for cardioversion	256, 257		
propafenone for cardioversion	256, 257		
propranolol for PCI, see also beta-blockers	119		
PROTECT study	189		
psychosocial factors in CHD risk	27-28		
psychoeducational programmes for ACS	166-167		
Q			
quinidine for cardioversion	256		
		R	
		RACE	254
		radiofrequency for atrial fibrillation	268
		radionuclide myocardial perfusion imaging	98
		RALES	246
		rapid access heart failure clinic	201
		rapid smoking for smoking cessation	37
		rate versus rhythm control for atrial fibrillation	253-254
		reduced	
		or modified dietary fat intake	41
		sodium	58,87
		Renfrew/Paisley study	249
		REPLACE study	222
		retailers, interventions to reduce tobacco sales	33
		revascularisation	104-124, 231-236
		REVERSAL study	68
		risk stratification	55, 133-137, 168, 259, 260
		RITA	115
		S	
		SAFE study	253
		salt intake, as risk factor	82-83, 86
		SARIS	68
		SAVE study	206, 225
		school programmes	
		to reduce smoking	31
		to improve diet	39
		to increase exercise	47
		Second Heart Protection study	186
		self-management	
		for cholesterol reduction	70
		for smoking cessation	36
		of oral anticoagulation	265
		severe heart failure	244-247
		sibutramine for weight loss	86

This document is a supplement to, not a substitute for, professional skills and experience. Users are advised to consult the supporting evidence for a consideration of all the implications of a recommendation.

INDEX

U		X	
ultrasound guided interventions	114	ximelagatran for atrial fibrillation	266
unstable angina, see acute coronary syndromes			
upper gastrointestinal complications		Z	
and aspirin	142	zinc for primary prevention	23
and warfarin	265	zyban for smoking cessation	35
US Carvedilol	214		
V			
VALIANT	174		
valsartan	80, 174, 223		
VALUE study	80		
vegetables or salad, consumption in Wales/UK	7		
venous thromboembolism & HRT	25		
ventricular fibrillation & magnesium sulphate	140		
verapamil for secondary prevention	193		
see also calcium channel blockers			
V-HeFT	225		
vitamin C for primary prevention	23		
vitamin E			
for primary prevention	23		
for high risk/CHD diagnosed	101		
volunteer, non-medical responders	131		
W			
waist circumference & CHD risk	18		
warfarin, see also anticoagulants			
for atrial fibrillation	261-268		
for secondary prevention	191		
for stable angina/CHD	102		
WATCH study	224		
Whitehall II study	27		
work site intervention to promote exercise	45		

Bwletinau Tystiolaeth ar Iechyd Cymru

Health Evidence Bulletins - Wales

Division of Information Services, University of Wales College of Medicine, Cardiff CF14 4XN

Tel: 029 2074 5142 Fax: 029 2074 3574 Email: MannMK@cardiff.ac.uk

<http://hebw.uwcm.ac.uk> (World Wide) <http://nwww.wales.nhs.uk/hebw> (NHS Wales only)